|
1. Biologie
|
|
|
|
|
|
2.10 Etiologie - Alcool
|
|
|
|
|
|
3.1 Tabac
|
|
|
One-fourth of US cancer deaths linked with one thing: smoking [STAT]
|
|
|
|
|
|
The
study found that at least 167,000 cancer deaths in 2014 — about 29
percent of all US cancer deaths — were attributable to smoking. Most of
the 10 states with the highest rates of smoking-attributable cancer
deaths were in the South, while most of the 10 states with the lowest
rates were in the North or West.
|
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.12 Immunothérapies
|
|
|
Fighting cancer with the power of immunity [MIT News]
|
|
|
|
|
|
In
the new study, the researchers used a combination of four different
therapies to activate both of the immune system’s two branches,
producing a coordinated attack that led to the complete disappearance of
large, aggressive tumors in mice.
|
|
|
|
|
|
|
Modified Immunotherapy Approach Shows Promise for Leukemia [NCI]
|
|
|
|
|
|
In
the phase I trial, researchers collected the immune cells, called
natural killer (NK) cells, from donors, manipulated them to be better
cancer killers, and infused the cells into patients with AML who had
previously exhausted all other treatment options.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer [Xconomy]
|
|
|
|
|
|
Roughly
a quarter of all advanced NSCLC patients have cancer with high PD-L1
levels, according to earlier studies from Merck. That restriction is
important. The new wave of cancer immunotherapies called checkpoint
inhibitors, which include pembrolizumab, work well for a minority of
patients, but doctors and researchers are only beginning to understand
the signs that might point to a benefit for some patients but not
others.
|
|
|
|
|
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|